Autek China Inc (300595) Fair Value & Analysis
Healthcare · CN · Market cap 10.0B CNY
Fair value as of: Jul 9, 2026
From 26 valuation models · updated 32 days ago
Share price +7.1% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥8.84 (bear) to ¥14.73 (bull), base ¥11.78. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 69/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥10.36 – ¥103.33 · fair‑value band ¥8.84 – ¥14.73 · the ¥11.38 price screens below the ¥11.78 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Autek China Inc (300595) currently trades at ¥11.38, while our model-based Fair Value estimate is ¥11.78, implying the stock looks roughly 3.5% fairly valued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Autek China Inc generated revenue of 1.8B CNY at a net margin of 25.3%. Revenue declined 3.9% year over year. It earns a return on equity of 9.8%. The balance sheet holds a net cash position of 540M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥8.84 (bear case) to ¥14.73 (bull case); at ¥11.38, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 4%, 300595 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥21.20) versus Asset-Based (¥3.68). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Autek China Inc. engages in the research and development, production, and sale of optometry products and related supporting products in China.
Full company description
Autek China Inc. engages in the research and development, production, and sale of optometry products and related supporting products in China. The company offers rigid contact lenses, rigid lens care products, myopia control products other than rigid glasses, visual function training products, dry eye/eye strain/presbyopia/accommodative hypoplasia treatment products, and eye health products. It also provides ophthalmic and optometry medical devices. Autek China Inc. was incorporated in 2000 and is based in Hefei, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Autek China Inc reported revenue of ¥1.8B in FY2025 versus ¥1.3B in FY2021, a compound +9.3%/yr. Reported net income was ¥480M in FY2025, compounding −3.6%/yr from FY2021.
Watch 300595: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Autek China Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Autek China Inc (300595) overvalued or undervalued?
What is the fair value of 300595?
What is the quality score of 300595?
What is the revenue of Autek China Inc (300595)?
What is the net profit margin of 300595?
Does Autek China Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Autek China Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.